CYTK CYTOKINETICS INC
Nasdaq · SEC CIK 1061983 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $52.26M 81 sales by 10 insiders
- Filings on record
- 559 since 2021-07-02, latest 2026-09-22 18:14
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Blum Robert I | Pres, CEO, Dir | — | $17.08M |
| Callos Andrew | EVP, Chief Commercial Off | — | $16.02M |
| Lee Sung | EVP, CFO | — | $5.70M |
| Malik Fady Ibraham | EVP Research, Development | — | $4.65M |
| Kaye Edward M. MD | Dir | — | $3.21M |
| HENDERSON JOHN T | Dir | — | $2.08M |
| WIERENGA WENDELL | Dir | — | $1.88M |
| PARSHALL B LYNNE | Dir | — | $1.36M |
| Landry Robert E | Dir | — | $146.8K |
| Harrington Robert Arthur | Dir | — | $143.6K |
Transactions 784
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-07-16 | 2025-07-15 | CYTK | Wysenski Nancy | Dir | A - Grant | $38.01 | +164 | 30.8K | +0.5% | +$6,234 | |
| 2025-07-16 | 2025-07-15 | CYTK | WIERENGA WENDALL | Dir | A - Grant | $38.01 | +164 | 32.3K | +0.5% | +$6,234 | |
| 2025-07-16 | 2025-07-15 | CYTK | HENDERSON JOHN T | Dir | A - Grant | $38.01 | +559 | 74.2K | +0.8% | +$21.2K | |
| 2025-07-16 | 2025-07-15 | CYTK | Harrington Robert Arthur | Dir | A - Grant | $38.01 | +328 | 22.6K | +1% | +$12.5K | |
| 2025-07-15 | 2025-07-14 | CYTK | Blum Robert I | Pres, CEO, Dir | S - Sale | $38.15 | -5,000 | 393.1K | -1% | -$190.8K | |
| D | 2025-07-08 | 2025-07-08 | CYTK | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $33.76 | -2,000 | 140.6K | -1% | -$67.5K |
| D | 2025-07-08 | 2025-07-08 | CYTK | Malik Fady Ibraham | EVP Research, Development | M - OptEx | $10.60 | +2,000 | 142.6K | +1% | +$21.2K |
| 2025-07-02 | 2025-07-01 | CYTK | Blum Robert I | Pres, CEO, Dir | S - Sale | $33.55 | -5,000 | 398.1K | -1% | -$167.8K | |
| D | 2025-06-17 | 2025-06-17 | CYTK | Malik Fady Ibraham | EVP Research, Development | M - OptEx | $10.60 | +2,000 | 142.6K | +1% | +$21.2K |
| D | 2025-06-17 | 2025-06-17 | CYTK | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $32.91 | -2,000 | 140.6K | -1% | -$65.8K |
| 2025-06-16 | 2025-06-16 | CYTK | Blum Robert I | Pres, CEO, Dir | S - Sale | $33.80 | -5,000 | 403.1K | -1% | -$169.0K | |
| 2025-06-05 | 2025-06-05 | CYTK | Callos Andrew | EVP, Chief Commercial Off | S - Sale | $32.04 | -8,659 | 52.0K | -14% | -$277.4K | |
| 2025-06-05 | 2025-06-05 | CYTK | Kaye Edward M. MD | Dir | S - Sale | $32.10 | -3,636 | 29.7K | -11% | -$116.7K | |
| 2025-06-03 | 2025-06-02 | CYTK | Lee Sung | EVP, CFO | F - Tax | $31.21 | -4,965 | 69.5K | -7% | -$155.0K | |
| D | 2025-06-03 | 2025-06-03 | CYTK | Malik Fady Ibraham | EVP Research, Development | M - OptEx | $10.60 | +2,000 | 142.6K | +1% | +$21.2K |
| D | 2025-06-03 | 2025-06-03 | CYTK | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $31.88 | -2,000 | 140.6K | -1% | -$63.8K |
| 2025-06-02 | 2025-06-02 | CYTK | Blum Robert I | Pres, CEO, Dir | S - Sale | $31.22 | -5,000 | 408.1K | -1% | -$156.1K | |
| D | 2025-05-20 | 2025-05-20 | CYTK | Malik Fady Ibraham | EVP Research, Development | M - OptEx | $10.60 | +2,000 | 142.3K | +1% | +$21.2K |
| D | 2025-05-20 | 2025-05-20 | CYTK | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $31.98 | -2,000 | 140.3K | -1% | -$64.0K |
| D | 2025-05-19 | 2025-05-14 | CYTK | Harrington Robert Arthur | Dir | A - Grant | $0.00 | +7,333 | 22.3K | +49% | $0 |
| 2025-05-16 | 2025-05-16 | CYTK | Blum Robert I | Pres, CEO, Dir | S - Sale | $30.93 | -5,000 | 412.6K | -1% | -$154.7K | |
| D | 2025-05-15 | 2025-05-14 | CYTK | PARSHALL B LYNNE | Dir | A - Grant | $0.00 | +7,333 | 27.9K | +36% | $0 |
| 2025-05-15 | 2025-05-15 | CYTK | Bhanji Muna | Dir | S - Sale | $29.73 | -1,454 | 23.5K | -6% | -$43.2K | |
| D | 2025-05-14 | 2025-05-14 | CYTK | HENDERSON JOHN T | Dir | A - Grant | $0.00 | +7,333 | 73.7K | +11% | $0 |
| D | 2025-05-14 | 2025-05-14 | CYTK | Landry Robert E | Dir | A - Grant | $0.00 | +7,333 | 7,333 | New | $0 |
| D | 2025-05-14 | 2025-05-14 | CYTK | Wysenski Nancy | Dir | A - Grant | $0.00 | +7,333 | 30.6K | +32% | $0 |
| D | 2025-05-14 | 2025-05-14 | CYTK | Bhanji Muna | Dir | A - Grant | $0.00 | +7,333 | 25.0K | +42% | $0 |
| D | 2025-05-14 | 2025-05-14 | CYTK | WIERENGA WENDALL | Dir | A - Grant | $0.00 | +7,333 | 32.2K | +30% | $0 |
| D | 2025-05-14 | 2025-05-14 | CYTK | Kaye Edward M. MD | Dir | A - Grant | $0.00 | +7,333 | 33.3K | +28% | $0 |
| D | 2025-05-06 | 2025-05-06 | CYTK | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $35.01 | -2,000 | 140.3K | -1% | -$70.0K |
| D | 2025-05-06 | 2025-05-06 | CYTK | Malik Fady Ibraham | EVP Research, Development | M - OptEx | $10.60 | +2,000 | 142.3K | +1% | +$21.2K |
| 2025-05-05 | 2025-05-05 | CYTK | Callos Andrew | EVP, Chief Commercial Off | S - Sale | $36.68 | -4,002 | 60.7K | -6% | -$146.8K | |
| 2025-04-29 | 2025-04-29 | CYTK | Blum Robert I | Pres, CEO, Dir | S - Sale | $40.96 | -5,000 | 417.6K | -1% | -$204.8K | |
| D | 2025-04-22 | 2025-04-22 | CYTK | Malik Fady Ibraham | EVP Research, Development | M - OptEx | $10.60 | +2,000 | 142.3K | +1% | +$21.2K |
| D | 2025-04-22 | 2025-04-22 | CYTK | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $38.11 | -2,000 | 140.3K | -1% | -$76.2K |
| D | 2025-04-21 | 2025-04-21 | CYTK | WIERENGA WENDALL | Dir | S - Sale+OE | $38.46 | -20.0K | 24.8K | -45% | -$769.2K |
| D | 2025-04-21 | 2025-04-21 | CYTK | WIERENGA WENDALL | Dir | M - OptEx | $6.21 | +20.0K | 44.8K | +80% | +$124.2K |
| D | 2025-04-16 | 2025-04-15 | CYTK | HENDERSON JOHN T | Dir | S - Sale+OE | $38.66 | -3,190 | 66.3K | -5% | -$123.3K |
| D | 2025-04-16 | 2025-04-15 | CYTK | HENDERSON JOHN T | Dir | M - OptEx | $6.21 | +20.0K | 69.5K | +40% | +$124.2K |
| 2025-04-16 | 2025-04-15 | CYTK | Wysenski Nancy | Dir | A - Grant | $38.56 | +162 | 23.3K | +0.7% | +$6,247 | |
| 2025-04-16 | 2025-04-15 | CYTK | Kaye Edward M. MD | Dir | A - Grant | $38.56 | +324 | 26.0K | +1% | +$12.5K | |
| 2025-04-16 | 2025-04-15 | CYTK | Harrington Robert Arthur | Dir | A - Grant | $38.56 | +324 | 15.0K | +2% | +$12.5K | |
| 2025-04-16 | 2025-04-15 | CYTK | HENDERSON JOHN T | Dir | A - Grant | $38.56 | +551 | 66.3K | +0.8% | +$21.2K | |
| 2025-04-16 | 2025-04-15 | CYTK | WIERENGA WENDALL | Dir | A - Grant | $38.56 | +162 | 24.8K | +0.7% | +$6,247 | |
| 2025-04-10 | 2025-04-10 | CYTK | Blum Robert I | Pres, CEO, Dir | S - Sale | $36.77 | -5,000 | 422.6K | -1% | -$183.9K | |
| D | 2025-04-08 | 2025-04-08 | CYTK | Malik Fady Ibraham | EVP Research, Development | M - OptEx | $10.60 | +2,000 | 142.3K | +1% | +$21.2K |
| D | 2025-04-08 | 2025-04-08 | CYTK | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $36.18 | -2,000 | 140.3K | -1% | -$72.4K |
| 2025-04-07 | 2025-04-07 | CYTK | Callos Andrew | EVP, Chief Commercial Off | S - Sale | $35.78 | -2,886 | 64.7K | -4% | -$103.3K | |
| 2025-04-04 | 2025-04-03 | CYTK | Harrington Robert Arthur | Dir | S - Sale | $39.43 | -450 | 14.7K | -3% | -$17.7K | |
| 2025-03-31 | 2025-03-31 | CYTK | Blum Robert I | Pres, CEO, Dir | S - Sale | $40.75 | -15.0K | 427.6K | -3% | -$611.2K | |
| 2025-03-19 | 2025-03-19 | CYTK | Malik Fady Ibraham | EVP Research, Development | G - Gift | $0.00 | -200 | 140.3K | -0.1% | $0 | |
| D | 2025-03-18 | 2025-03-14 | CYTK | Lee Sung | EVP, CFO | A - Grant | $0.00 | +32.7K | 74.4K | +78% | $0 |
| D | 2025-03-18 | 2025-03-14 | CYTK | Blum Robert I | Pres, CEO, Dir | A - Grant | $0.00 | +116.1K | 480.3K | +32% | $0 |
| D | 2025-03-18 | 2025-03-14 | CYTK | Callos Andrew | EVP, Chief Commercial Off | A - Grant | $0.00 | +32.7K | 70.3K | +87% | $0 |
| D | 2025-03-18 | 2025-03-14 | CYTK | Malik Fady Ibraham | EVP Research, Development | A - Grant | $0.00 | +39.5K | 144.8K | +37% | $0 |
| D | 2025-03-18 | 2025-03-18 | CYTK | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $43.58 | -2,000 | 140.5K | -1% | -$87.2K |
| D | 2025-03-18 | 2025-03-18 | CYTK | Malik Fady Ibraham | EVP Research, Development | M - OptEx | $10.60 | +2,000 | 142.5K | +1% | +$21.2K |
| 2025-03-17 | 2025-03-17 | CYTK | Callos Andrew | EVP, Chief Commercial Off | S - Sale | $44.38 | -2,775 | 34.9K | -7% | -$123.2K | |
| 2025-03-17 | 2025-03-17 | CYTK | Blum Robert I | Pres, CEO, Dir | S - Sale | $44.65 | -25.0K | 339.2K | -7% | -$1.12M | |
| 2025-03-17 | 2025-03-17 | CYTK | Malik Fady Ibraham | EVP Research, Development | S - Sale | $44.38 | -4,389 | 101.0K | -4% | -$194.8K | |
| 2025-03-17 | 2025-03-17 | CYTK | Blum Robert I | Pres, CEO, Dir | S - Sale | $44.38 | -12.6K | 326.5K | -4% | -$561.3K | |
| D | 2025-03-17 | 2025-03-17 | CYTK | Callos Andrew | EVP, Chief Commercial Off | M - OptEx | $23.26 | +20.9K | 58.6K | +55% | +$486.1K |
| D | 2025-03-17 | 2025-03-17 | CYTK | Callos Andrew | EVP, Chief Commercial Off | S - Sale+OE | $45.14 | -20.9K | 37.7K | -36% | -$943.4K |
| D | 2025-03-14 | 2025-03-14 | CYTK | Callos Andrew | EVP, Chief Commercial Off | S - Sale+OE | $45.00 | -100 | 37.7K | -0.3% | -$4,500 |
| D | 2025-03-14 | 2025-03-14 | CYTK | Callos Andrew | EVP, Chief Commercial Off | M - OptEx | $23.26 | +100 | 37.8K | +0.3% | +$2,326 |
| 2025-03-13 | 2025-03-13 | CYTK | Callos Andrew | EVP, Chief Commercial Off | S - Sale | $43.62 | -26.8K | 37.7K | -42% | -$1.17M | |
| 2025-03-07 | 2025-03-06 | CYTK | Blum Robert I | Pres, CEO, Dir | S - Sale | $43.44 | -17.0K | 364.2K | -4% | -$737.2K | |
| 2025-03-07 | 2025-03-06 | CYTK | Malik Fady Ibraham | EVP Research, Development | S - Sale | $43.27 | -8,228 | 105.4K | -7% | -$356.0K | |
| 2025-03-07 | 2025-03-06 | CYTK | Callos Andrew | EVP, Chief Commercial Off | S - Sale | $43.27 | -3,341 | 64.4K | -5% | -$144.6K | |
| 2025-03-05 | 2025-03-03 | CYTK | Malik Fady Ibraham | EVP Research, Development | S - Sale | $42.88 | -2,449 | 113.6K | -2% | -$105.0K | |
| 2025-03-05 | 2025-03-03 | CYTK | Blum Robert I | Pres, CEO, Dir | S - Sale | $42.88 | -8,743 | 406.2K | -2% | -$374.9K | |
| 2025-03-05 | 2025-03-05 | CYTK | Blum Robert I | Pres, CEO, Dir | S - Sale | $43.23 | -25.0K | 381.2K | -6% | -$1.08M | |
| 2025-03-05 | 2025-03-03 | CYTK | Callos Andrew | EVP, Chief Commercial Off | S - Sale | $42.88 | -1,114 | 67.8K | -2% | -$47.8K | |
| D | 2025-03-04 | 2025-03-04 | CYTK | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $42.50 | -2,000 | 116.1K | -2% | -$85.0K |
| D | 2025-03-04 | 2025-03-04 | CYTK | Malik Fady Ibraham | EVP Research, Development | M - OptEx | $10.60 | +2,000 | 118.1K | +2% | +$21.2K |
| 2025-03-04 | 2025-03-04 | CYTK | Harrington Robert Arthur | Dir | S - Sale | $42.50 | -900 | 15.1K | -6% | -$38.2K | |
| D | 2025-02-18 | 2025-02-18 | CYTK | Malik Fady Ibraham | EVP Research, Development | M - OptEx | $10.60 | +2,000 | 118.1K | +2% | +$21.2K |
| D | 2025-02-18 | 2025-02-18 | CYTK | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $45.98 | -2,000 | 116.1K | -2% | -$92.0K |
| D | 2025-02-04 | 2025-02-04 | CYTK | Malik Fady Ibraham | EVP Research, Development | M - OptEx | $10.60 | +2,000 | 118.1K | +2% | +$21.2K |
| D | 2025-02-04 | 2025-02-04 | CYTK | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $48.06 | -2,000 | 116.1K | -2% | -$96.1K |
| D | 2025-01-21 | 2025-01-21 | CYTK | Malik Fady Ibraham | EVP Research, Development | M - OptEx | $10.60 | +2,000 | 118.1K | +2% | +$21.2K |
| D | 2025-01-21 | 2025-01-21 | CYTK | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $45.92 | -2,000 | 116.1K | -2% | -$91.8K |
| D | 2025-01-10 | 2025-01-07 | CYTK | Malik Fady Ibraham | EVP Research, Development | M - OptEx | $10.60 | +2,000 | 118.1K | +2% | +$21.2K |
| D | 2025-01-10 | 2025-01-07 | CYTK | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $49.32 | -2,000 | 116.1K | -2% | -$98.6K |
| 2025-01-06 | 2025-01-02 | CYTK | HENDERSON JOHN T | Dir | A - Grant | $48.93 | +434 | 49.0K | +0.9% | +$21.2K | |
| 2025-01-06 | 2025-01-02 | CYTK | Wysenski Nancy | Dir | A - Grant | $48.93 | +127 | 23.1K | +0.6% | +$6,214 | |
| 2025-01-06 | 2025-01-02 | CYTK | WIERENGA WENDALL | Dir | A - Grant | $48.93 | +127 | 24.7K | +0.5% | +$6,214 | |
| 2025-01-06 | 2025-01-02 | CYTK | Harrington Robert Arthur | Dir | A - Grant | $48.93 | +255 | 16.0K | +2% | +$12.5K | |
| 2025-01-06 | 2025-01-02 | CYTK | Kaye Edward M. MD | Dir | A - Grant | $48.93 | +255 | 25.6K | +1% | +$12.5K | |
| D | 2024-12-16 | 2024-12-16 | CYTK | WIERENGA WENDALL | Dir | S - Sale+OE | $48.61 | -742 | 24.6K | -3% | -$36.1K |
| D | 2024-12-16 | 2024-12-16 | CYTK | WIERENGA WENDALL | Dir | M - OptEx | $7.37 | +742 | 25.3K | +3% | +$5,469 |
| DM | 2024-12-12 | 2024-12-11 | CYTK | HENDERSON JOHN T | Dir | M - OptEx | $7.37 | +11.9K | 40.2K | +42% | +$87.5K |
| D | 2024-12-12 | 2024-12-11 | CYTK | HENDERSON JOHN T | Dir | S - Sale+OE | $50.42 | -1,780 | 38.5K | -4% | -$89.7K |
| D | 2024-12-10 | 2024-12-10 | CYTK | Malik Fady Ibraham | EVP Research, Development | M - OptEx | $7.96 | +5,300 | 123.4K | +4% | +$42.2K |
| DM | 2024-12-10 | 2024-12-10 | CYTK | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $50.64 | -7,300 | 118.1K | -6% | -$369.6K |
| M | 2024-12-05 | 2024-12-03 | CYTK | Lee Sung | EVP, CFO | A - Grant | $0.00 | +8,607 | 39.0K | +28% | $0 |
| 2024-12-05 | 2024-12-03 | CYTK | Lee Sung | EVP, CFO | F - Tax | $51.51 | -1,536 | 37.5K | -4% | -$79.1K | |
| M | 2024-12-05 | 2024-12-03 | CYTK | Blum Robert I | Pres, CEO, Dir | A - Grant | $0.00 | +23.1K | 414.9K | +6% | $0 |
| 2024-12-05 | 2024-12-03 | CYTK | Blum Robert I | Pres, CEO, Dir | F - Tax | $51.51 | -5,843 | 403.4K | -1% | -$301.0K | |
| M | 2024-12-05 | 2024-12-03 | CYTK | Malik Fady Ibraham | EVP Research, Development | A - Grant | $0.00 | +8,000 | 118.1K | +7% | $0 |
Purchase Sale Sale after option exercise All abbreviations